Important Information for Investors: Viatris Securities Class Action Lawsuit
New York, NY and New Orleans, LA– Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. (Viatris or the Company) (NasdaqGS: VTRS).
The lawsuit alleges that the Company and certain of its executives and directors made false and/or misleading statements and/or failed to disclose that:
- The Company’s financial statements for the periods from August 8, 2024 to February 26, 2025, inclusive (the “Class Period”), contained material misstatements and omissions regarding the Company’s business, operations, and financial condition;
- The Company’s revenue growth was being driven by one-time events and unsustainable price increases, rather than organic growth;
- The Company’s cost savings initiatives were not as effective as represented;
- The Company’s merger with Pfizer’s Upjohn business was not expected to deliver the synergies and cost savings as represented;
If you purchased Viatris securities during the Class Period, you may be eligible to recover your losses. To be eligible to serve as lead plaintiff, you must meet certain legal requirements. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member and do nothing.
Effect on Individual Investors
If the allegations in the lawsuit are proven, Viatris investors who purchased the Company’s securities during the Class Period may be able to recover their losses. The lead plaintiff will act on behalf of all Class Members in the lawsuit. The lead plaintiff’s counsel will conduct the litigation on a contingency basis, meaning they will only be paid if there is a recovery for Class Members.
Effect on the World
The securities class action lawsuit against Viatris is significant because it raises important questions about the accuracy and transparency of the Company’s financial statements and business practices during the Class Period. The lawsuit highlights the importance of companies providing accurate and complete information to investors, and the role of the securities class action process in holding companies accountable for misrepresentations.
The outcome of the lawsuit may have implications for the pharmaceutical industry as a whole, as it could set a precedent for future cases involving financial misstatements and disclosures. It may also impact investor confidence in the industry and the market as a whole.
Conclusion
If you purchased Viatris securities during the Class Period and believe you may be eligible to recover your losses, you are encouraged to contact KSF as soon as possible. KSF continues to investigate the merits of the case and will provide updates as additional information becomes available.
The securities class action lawsuit against Viatris is an important reminder for investors to carefully evaluate the accuracy and completeness of the information provided by companies before making investment decisions. The outcome of the lawsuit may have implications for the pharmaceutical industry and the securities markets as a whole.
If you have any questions or would like to discuss this matter further, please contact KSF Partner, former Attorney General of Louisiana, Charles C. Foti, Jr., at [email protected] or call toll-free at 1-877-515-1850.
About Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) is a New York-based law firm focusing on securities class actions and shareholder derivative suits. KSF’s team of attorneys has represented investors over the past decade in some of the largest securities class action settlements in history.
